DLD Asset Management LP Has $3.08 Million Stock Holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC)

DLD Asset Management LP trimmed its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 40.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,200 shares of the company's stock after selling 23,550 shares during the quarter. DLD Asset Management LP owned about 0.11% of iRhythm Technologies worth $3,084,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of IRTC. R Squared Ltd acquired a new stake in shares of iRhythm Technologies during the 4th quarter worth $45,000. Van ECK Associates Corp raised its holdings in shares of iRhythm Technologies by 41.3% in the 4th quarter. Van ECK Associates Corp now owns 554 shares of the company's stock worth $50,000 after purchasing an additional 162 shares during the period. Quarry LP acquired a new position in shares of iRhythm Technologies in the 3rd quarter valued at about $59,000. Nisa Investment Advisors LLC lifted its stake in shares of iRhythm Technologies by 166.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,037 shares of the company's stock valued at $94,000 after purchasing an additional 648 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in iRhythm Technologies during the third quarter valued at approximately $119,000.

iRhythm Technologies Stock Performance

iRhythm Technologies stock traded down $5.58 during mid-day trading on Friday, hitting $100.34. 405,490 shares of the company's stock traded hands, compared to its average volume of 456,256. iRhythm Technologies, Inc. has a one year low of $55.92 and a one year high of $128.52. The company has a market cap of $3.15 billion, a PE ratio of -27.57 and a beta of 1.45. The firm has a 50 day moving average price of $107.62 and a 200 day moving average price of $91.00. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00.

Remove Ads

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.30. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The company had revenue of $164.33 million for the quarter, compared to the consensus estimate of $158.30 million. On average, equities analysts forecast that iRhythm Technologies, Inc. will post -1.98 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IRTC shares. Wells Fargo & Company lifted their target price on shares of iRhythm Technologies from $86.00 to $104.00 and gave the company an "equal weight" rating in a report on Friday, February 21st. Needham & Company LLC increased their target price on iRhythm Technologies from $125.00 to $138.00 and gave the company a "buy" rating in a research note on Friday, February 21st. StockNews.com upgraded iRhythm Technologies from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Canaccord Genuity Group lifted their price objective on shares of iRhythm Technologies from $125.00 to $152.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Finally, Oppenheimer upped their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $119.73.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.